Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply.
University of Athens, School of Medicine, Athens 11528, Greece. Electronic address: mdimop@med.uoa.gr.
Meletios A
MA
Dimopoulos
University of Nantes, Nantes, France.
Philippe
P
Moreau
University of Turin, Turin, Italy.
Antonio
A
Palumbo
National University of Singapore, Singapore.
Wee-Joo
WJ
Chng
Amgen, South San Francisco, CA, USA.
Shibao
S
Feng
D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols; D001897:Boronic Acids; D000069286:Bortezomib; D006801:Humans; D009101:Multiple Myeloma; D012008:Recurrence
D000970:Antineoplastic Agents; D001897:Boronic Acids; D000069286:Bortezomib